IVF

INVO Fertility, Inc. (IVF) - Q1 2025 10-Q Summary

Business Context and Reporting Period

This Quarterly Report on Form 10-Q covers the period ended March 31, 2025. INVO Fertility, Inc. (formerly NAYA Therapeutics, Inc.) is a healthcare services company focused on the fertility marketplace, operating INVO Centers and acquired IVF clinics (Wisconsin Fertility Institute). The Company recently announced a strategic pivot to divest its majority stake in NAYA Therapeutics (oncology/autoimmune) to focus exclusively on fertility, reflected in its name change to "INVO Fertility, Inc." and ticker symbol change to "IVF" in April 2025.

Key Financial Metrics

Material Changes vs. Prior Period

• Significant Impairment Loss: The Net Loss increased dramatically to $17.4 million, primarily driven by a non-cash impairment loss of $14.6 million related to goodwill from the NAYA Therapeutics acquisition. This impairment was triggered by a decline in the Company's stock price.
• Operating Expenses: Total operating expenses rose to $18.7 million from $3.1 million. This includes a $266,000 increase in R&D expenses and a $1.1 million increase in SG&A expenses, largely due to the consolidation of NAYA Therapeutics.
• Revenue Growth: Total revenue increased modestly by approximately 4% year-over-year, with Clinic Revenue rising to $1.62 million.
• Capital Structure: The Company executed a 1-for-12 reverse stock split in March 2025. In January 2025, it completed a public offering raising net proceeds of $8.7 million, which was used to redeem $4.0 million of Series C-2 Preferred Stock and repay approximately $1.1 million in debt.

Guidance, Outlook, and Risks

• Strategic Pivot: Management plans to divest a majority interest in NAYA Therapeutics in Q2 2025 to refocus on fertility services. The Company intends to retain a minority stake in NAYA.
• Liquidity and Going Concern: The Company has an accumulated deficit of $84.9 million and negative working capital of approximately $17.1 million. The independent auditor's report for the prior year expressed substantial doubt about the Company's ability to continue as a going concern. The Company expects to continue incurring losses and will require additional debt or equity financing to meet liquidity needs.
• Legal Proceedings: A binding term sheet was signed on May 14, 2025, to settle litigation with Dr. Elizabeth Pritts regarding the WFI acquisition. The settlement requires a total payment of $5.0 million, with $525,000 paid immediately and the remainder payable through December 2026.
• Debt Defaults: The Company disclosed events of default under its 7% Senior Secured Convertible Debenture (principal $3.9 million) due to missed interest and redemption payments. The total amount in arrears is approximately $1.5 million. The holder has agreed in principle to an amended debenture.
• Internal Controls: Management concluded that disclosure controls and procedures were not effective as of March 31, 2025, citing material weaknesses in segregation of duties and accounting resources.

Investor Verification Checklist

• Divestiture Timeline: Verify the progress and definitive agreement status for the divestiture of NAYA Therapeutics, as this is critical to the Company's strategic refocus.
• Settlement Funding: Confirm the Company's ability to fund the $5.0 million settlement with Dr. Pritts, given current cash levels of $0.8 million and negative operating cash flow.
• Debt Restructuring: Monitor the finalization of the amended debenture agreement with Five Narrow Lane LP to resolve the current default status.
• Capital Raises: Assess the likelihood and terms of future equity or debt financing required to sustain operations and fund clinic acquisitions.
• Internal Control Remediation: Review updates on the remediation of material weaknesses in internal controls over financial reporting.